Spermidine treatment significantly increased LC3 (p < 0.01) and Beclin-1 (p < 0.05) compared with the Diabetes group, yet values for both markers remained lower than in Controls (p < 0.01 for each). This evidence concerns the gene MAP1LC3A and diabetes mellitus.